澤璟製藥(688266.SH)半年度淨虧損1.29億元
格隆匯 8 月 16日丨澤璟製藥(688266.SH)發佈2020年半年度報告，實現營業收入0元；歸屬於上市公司股東的淨虧損1.29億元，上年同期淨虧損為3.41億元；基本每股虧損0.56元。
截至2020年6月30日，公司尚未盈利且存在累計未彌補虧損，主要原因是公司仍處於產品研發階段、研發支出較大。未來一段時間，公司將存在累計未彌補虧損及持續虧損並將面臨如下潛在風險：
公司仍處於產品研發階段、研發支出較大，公司尚無藥品獲得商業銷售批准，亦無任何藥品銷售收入，因此，公司未來一定期間無法盈利或無法進行利潤分配。公司未來虧損淨額的多少將取決於公司藥品研發項目的數量及範圍、與該等項目有關的成本、獲批產品進行商業化生產的成本、公司產生收入的能力等方面。如公司在研藥品未能完成臨牀試驗或未能取得監管部門批准，或未能獲得市場認可及商業化，公司可能將始終無法盈利；即使公司未來能夠盈利，但亦可能無法保持持續盈利。公司短期內無法現金分紅，將對股東的投資收益造成一定程度不利影響。
報告期內，公司持續加大研發投入，上半年研發投入金額12934.23萬元，同比增加70.84%，其中委託臨牀前試驗服務費同比增加123.27%，委託臨牀試驗服務費同比增加208.53%，雖然2020年上半年公司的臨牀試驗在一定程度受到了疫情影響，但是公司積極開展各項工作，有力推進了臨牀試驗進程，各產品管線取得積極進展。
截至報告披露日，公司的產品管線擁有12個主要在研藥品的30項在研項目，其中5個在研藥品處於NDA、II/III期臨牀試驗階段、1個處於I/II期臨牀試驗階段、1個處於IND階段、5個處於臨牀前研發階段。已經進入臨牀研究階段的在研新藥包括甲苯磺酸多納非尼片、外用重組人凝血酶、鹽酸傑克替尼片、奧卡替尼膠囊、注射用重組人促甲狀腺激素及鹽酸傑克替尼乳膏。ZG5266處於IND申請階段。小分子新藥ZG0588及ZG170607、抗腫瘤雙靶點抗體新藥ZG005及ZG006、抗腫瘤三靶點抗體ZGGS001處於臨牀前研發階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
